Lazertinib Mesylate

Johnson & Johnson now expects to reel in between $92.7 billion to $93.1 billion in total sales for the year, a $2 billion increase compared with the guidance it provided in April. Leading up to the entry of the first Stelara biosimilars in the U.S. at the start of 2025, executives at Johnson & Johnson remained steadfast in their belief that the company could maintain revenue growth despite the blockbuster drug’s toppling over the patent cliff.Now, after setting an innovative medicines sales record in the year’s second quarter against the backdrop of that biosimilar erosion, it appears J&J’s confidence was well placed.For the first time, J&J’s global innovative medicines sales have reached more than $15 billion in a single quarter, the company noted (PDF) in a July 16 earnings presentation.That performance, buoyed by a slate of promising launches in oncology, immunology and neurology, contributed to a total companywide sales haul of $23.7 billion for the second quarter, nearly a 6% increase from the sum J&J recorded for the same period in 2024.J&J logged those gains despite sales of Stelara—which peaked at around $11 billion in 2023—plunging more than $1.2 billion year over year. For the second quarter, the inflammatory med posted worldwide sales of around $1.7 billion, down roughly 43% compared to its performance in 2024’s second quarter. “We had 13 brands that were growing double digits [in Q2], and as we take a look at those, the vast majority of those are not only our growth drivers for today and tomorrow but are also key growth drivers out through the end of the decade,” Jennifer Taubert, J&J’s executive vice president of innovative medicine, said on a conference call Wednesday.Taubert spotlighted the performance of cancer drugs like Darzalex, which grew sales 23% to $3.5 billion; Carvykti, which recorded sales of $439 million; and Erleada, which rose 23% to $908 million. She also noted that the company is “really pleased with the launch and uptake thus far” of Rybrevant plus Lazcluze, which won the FDA’s blessing last August to treat certain patients with newly diagnosed non-small cell lung cancer.Together, that performance bodes well for J&J’s overall ambitions in cancer, with CEO Joaquin Duato reiterating on the company’s earnings call that “[w]e expect to become the number one oncology company by 2030 with sales of more than $50 billion.”Beyond cancer, Taubert touted Tremfya’s “great start” in ulcerative colitis and Crohn’s disease, where the burgeoning immunology drug picked up FDA nods in September and March, respectively.  Altogether, Tremfya—which is scooping up indications previously dominated by Stelara—grew sales 31% to $1.2 billion in the second quarter. Given the strong showing in the quarter, J&J now expects to reel in between $92.7 billion and $93.1 billion in total sales for the year, a $2 billion increase over the guidance it provided in April.Elsewhere, executives at the company praised the passing of President Donald Trump’s "big, beautiful bill," with Chief Financial Officer Joe Wolk noting that the law “provides certainty for a previously announced $55 billion commitment to invest here in the United States.”From J&J's perspective, Wolk spotlighted several favorable provisions in the bill, including “permanent expensing for domestic R&D spend, permanent bonus depreciation and 100% expensing of qualified production property, including our newly planned facility in North Carolina.”

Johnson & Johnson on Wednesday reported quarterly prescription drug sales that for the first time surpassed $15 billion, highlighting the strength of the pharmaceutical companys portfolio during a year in which its formerly top-selling drug lost market exclusivity.Second quarter sales for J&Js pharmaceuticals business reached $15.2 billion between April and June, nearly 4% higher than the same period last year on an operational basis. Overall second quarter sales were up 4.6% on the same basis to total $23.7 billion, beating Wall Street forecasts.J&J now expects higher operational growth for 2025, increasing the midpoint of its guidance range for both adjusted sales and earnings per share.The company also halved its estimates for how much U.S. tariffs would weigh on its business this year. It now anticipates a roughly $200 million hit, exclusively within its medical device unit. President Donald Trump has said further levies on pharmaceuticals are coming soon, but indicated the duties would be phased in, potentially giving drugmakers time to adjust their operations and stockpile inventory.J&J shares jumped by more than 6% Wednesday morning following its earnings release.No other healthcare company has grown through the loss of exclusivity of a multibillion-dollar product in the first year, in our case Stelara, J&J CEO Joaquin Duato said on a conference call with analysts, referring to the companys 16-year-old psoriasis and inflammatory bowel disease medicine.Stelara sales during the quarter fell by 43% year over year, to $1.7 billion.J&J has a newer drug, Tremfya, that it has positioned as a successor to Stelara in many of the same diseases and hopes will eventually grow into a $10 billion-a-year product. Sales in the second quarter rose 30% year over year to $1.2 billion as more doctors prescribed it for Crohns disease and ulcerative colitis.But its J&Js oncology business thats providing the most significant counterweight to Stelaras loss of exclusivity. Overall cancer drug sales were $6.3 billion between April and June, more than $1 billion higher than in the same period last year.Over half of that total came from J&Js multiple myeloma medicine Darzalex, which is one of several drugs the company sells for the blood cancer. Duato claimed about 80% of all multiple myeloma patients receive a J&J therapy as some point in their treatment.By the end of the decade, J&J predicts its oncology business will bring in $50 billion in annual sales, notably higher than what analysts on Wall Street currently estimate.Jennifer Taubert, head of the companys pharmaceuticals business, pointed to Darzalex and its multiple myeloma cell therapy Carvykti as key contributors to that goal. Two other J&J medicines, Tecvayli and Talvey, are also approved for the blood cancer, but are early in their respective launches.Taubert also highlighted a drug-device combination called TAR-200 that J&J is targeting for use in non-muscle invasive bladder cancer. That is probably the asset that has the biggest disconnect between our internal forecasts and what the Street expects, she said. If you take a look at 2028 consensus, we actually see our numbers at least three times higher.J&J previously detailed several other drugs for which analysts forecasts diverge from its own. One other is a combination of the medicines Rybrevant and Lazcluze, which are approved for a certain type of metastatic lung cancer. The company aims to win U.S. clearance for a subcutaneous version of Rybrevant, but had its application rejected by the Food and Drug Administration in December.On Wednesdays call, Taubert said the agencys complete response letter related to a manufacturing question or two and J&J has since responded. '